Valuation of pharmaceutical and biotechnology assets and businesses requires a robust understanding of the sector. As a buyer of pharma and biotech assets, one wants to buy inexpensively, and as a seller of assets, one wants to secure a high value. It is vital for investors and corporations to understand the key factors on which biotech and pharma valuation depends. BiopharmaVantage, the pharma and biotech valuation consulting firm, discusses several of the key drivers such as the probability of success (attrition rate), discount rates (cost of capital), risk-adjusted NPV and DCF methods, etc. in the following articles:

What drives the value of biotechnology assets?
What are the key drivers of pharmaceutical valuation?
What is the optimal method for valuation of pharmaceutical and biotechnology assets?

About BiopharmaVantage
BiopharmaVantage is a life sciences consultancy that specializes in providing valuation services specifically for the biotechnology and pharmaceutical sector. If you would like to explore how we can assist you, then please contact us. For more visit

Katherine Mae
Business Development Manager
BiopharmaVantage, Oxford, UK